H.R. 7352: Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act of 2026

This bill, known as the Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act of 2026, aims to address the growing challenge of antimicrobial resistance by creating a program that encourages the development and availability of new antimicrobial drugs. The key components of the bill are as follows:

Purpose of the Bill

The bill is designed to achieve several goals:

• Stimulate research, development, and market access to essential antimicrobial medications.
• Ensure the proper use of these lifesaving medicines.
• Maintain high medical care standards in the U.S.
• Promote readiness within the national health system.
• Enhance the defense capabilities of the U.S. and its military.

Development of Antimicrobial Innovations

The bill proposes the establishment of a system of contracts between the Secretary of Health and Human Services and sponsors of eligible antimicrobial drugs to guarantee their availability. To qualify for these contracts, an antimicrobial must:

• Treat infections related to pathogens deemed urgent or serious threats by the Centers for Disease Control and Prevention (CDC).
• Address unmet medical needs.

Application Process

To enter into a contract, sponsors must submit an application within two years of their drug receiving approval. The application will not include pricing or development costs. The Secretary is tasked with reviewing these applications and must make decisions within 90 days. They will assess whether the antimicrobial meets a minimum score based on its potential contributions to patient care, its innovative characteristics, and its benefits to public health.

Contract Requirements

Contract holders will be obligated to ensure commercial availability of the drugs and to manage supplies. They must also track and report resistance data and educate healthcare professionals and patients on appropriate usage. Certain plans must be submitted to the Secretary regarding the drug's use and potential registration in other countries.

Financial Aspects

Annual payments to drug sponsors will range from $75 million to $300 million, adjusted for inflation and reduced by any revenues generated from the drug sales. The Secretary can halt payments if a contract is violated or if specific conditions are not met.

Duration of Contracts

Contracts will last for up to ten years or until a competing drug enters the market based on the same indications treated by the contract antimicrobial.

Advisory Group Establishment

An advisory group will be formed to provide recommendations on the most critical antimicrobial needs. This group will consist of medical experts, researchers, and patient advocates.

Encouraging Appropriate Antimicrobial Use

The bill also establishes a grant program to support healthcare facilities in implementing antimicrobial stewardship programs, aiming to optimize the use of these drugs and combat resistance.

Data Collection and Public Reporting

The Secretary will collect data on antimicrobial resistance trends and patterns of usage. This information will be made publicly available to facilitate transparency and inform stakeholders about the challenges and successes in combatting antimicrobial resistance.

Appropriations

The bill authorizes $6 billion for fiscal year 2026 to fund these initiatives, recognizing the financial urgency to tackle antimicrobial resistance.

Relevant Companies

None found